Edition:
India

Mylan Announces U.S. Launch Of Mesalamine Rectal Suppository, 1000 mg


Monday, 17 Dec 2018 

Dec 17 (Reuters) - Mylan NV ::MYLAN ADDS FIRST GENERIC FOR CANASA® RECTAL SUPPOSITORY TO GROWING GASTROENTEROLOGY PORTFOLIO.MYLAN NV - MESALAMINE RECTAL SUPPOSITORY HAS 180 DAYS OF GENERIC DRUG EXCLUSIVITY.MYLAN NV - ANNOUNCED U.S. LAUNCH OF MESALAMINE RECTAL SUPPOSITORY, 1000 MG, FIRST GENERIC VERSION OF ALLERGAN'S CANASA RECTAL SUPPOSITORY, 1000 MG.